TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Sees Significant Growth in Short Interest

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 181,400 shares, a growth of 474.1% from the December 31st total of 31,600 shares. Based on an average daily volume of 2,260,000 shares, the short-interest ratio is currently 0.1 days.

TC Biopharm Trading Up 2.0 %

TC Biopharm stock traded up $0.01 during midday trading on Wednesday, hitting $0.28. The stock had a trading volume of 510,660 shares, compared to its average volume of 869,764. TC Biopharm has a 52-week low of $0.25 and a 52-week high of $26.16. The firm’s fifty day moving average is $0.45 and its two-hundred day moving average is $2.63.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their price target on TC Biopharm from $5.60 to $2.40 and set a “buy” rating for the company in a research note on Friday, December 6th.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.